首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis
【24h】

The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis

机译:多奈哌齐和美金刚胺疗法的许可适应症治疗阿尔茨海默病痴呆症的行为和心理症状的功效:系统评价和荟萃分析

获取原文
           

摘要

Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. Results: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI –3.51, 95% confidence interval (CI) –5.75, –1.27], whereas this was not the case for memantine (WMD –1.65, 95% CI –4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (–1.86, 95% CI –5.71, 1.99; p = 0.34). Conclusion: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo.
机译:背景/目的:阿尔茨海默氏病(AD)中痴呆症(BPSD)的行为和心理症状会大大增加护理人员的负担。比较了多奈哌齐和美金刚在AD许可许可范围内管理BPSD的能力。方法:进行系统评价,随机效应荟萃分析和Bucher间接比较。结果:六项随机对照研究(4项多奈哌齐和2项美金刚)报告在许可的指征内使用,并具有适用于荟萃分析的神经精神病学清单(NPI)数据。与安慰剂相比,多奈哌齐改善了BPSD [NPI的加权平均差异(WMD)–3.51,95%置信区间(CI)–5.75,–1.27],而美金刚并非如此(WMD –1.65,95% CI –4.78,1.49)。多奈哌齐与美金刚在NPI中的WMD偏爱多奈哌齐,但无统计学意义(–1.86,95%CI –5.71,1.99; p = 0.34)。结论:与安慰剂相比,多奈哌齐在其许可的许可范围内对AD中BPSD的管理有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号